If you just saw that ERX1000 plus semaglutide boosted weight loss, here’s the short answer. The result comes from a mouse study that ERX Pharmaceuticals reports, and there are no human results for this combination yet. ERX1000 is an oral leptin sensitizer that is investigational, so it is not approved for any use.
In the company’s figures, diet-induced obese mice given the combination for 35 days had a 36% placebo-corrected body weight reduction. ERX1000 alone gave 18%, and semaglutide alone gave 14%. Those are the company’s numbers from animals, so treat them as early research, not a result you can expect.
Disclosure: For clarity, several links on this page are affiliate links. If you buy through them, this publication may earn a commission. Your price is the same either way.
ERX1000 quick facts, as of 2026-11-17
| Item | What the source says | Source and date |
|---|---|---|
| What it is | An orally administered small-molecule leptin sensitizer, according to ERX Pharmaceuticals | ERX news release, Nov. 16, 2026 |
| Approval status | Investigational and not approved for any use | As of 2026-11-17 |
| Study model | Diet-induced obese mice, 35 days | 2 Minute Medicine, Nov. 17, 2026 |
| Who presented it | Louis Aronne, at ObesityWeek 2026 on Nov. 15 | 2 Minute Medicine, Nov. 17, 2026 |
| Peer review | No peer-reviewed journal paper or DOI is cited | 2 Minute Medicine, Nov. 17, 2026 |
| Human trial | Phase 2a, assessing safety and tolerability in adults with obesity; completion expected in the second half of 2027 | ERX company news page, read Nov. 17, 2026 |
| Approved semaglutide (Wegovy) | Approved, with diet and physical activity, to reduce excess body weight in adults with obesity; in a 68-week trial, mean weight change was -14.9% with semaglutide vs -2.4% with placebo | FDA-approved Wegovy prescribing information, revised 06/2026 |
What happened in the mouse study?
ERX Pharmaceuticals announced the results in an ERX Pharmaceuticals’ news release dated November 16, 2026. According to 2 Minute Medicine’s summary, the study was performed by Physiogenex in France. Every number below is ERX’s own figure.
| Measure (company figures) | Combination | ERX1000 alone | Semaglutide alone |
|---|---|---|---|
| Placebo-corrected body weight reduction after 35 days | 36% | 18% | 14% |
| Weight-normalized grip strength improvement | 32% | 25% | 8% |
The company’s release calls the 36% figure “placebo-corrected.” 2 Minute Medicine uses that phrase and also “versus baseline” for the same number, so the company’s wording is the one to quote.
Food intake figures match across the two write-ups. 2 Minute Medicine reports food intake down 39% with the combination, 9% with semaglutide and 3% with ERX1000. The company release gives the same three figures, 39% vs 9% vs 3%.
ERX says the combination was synergistic, outperforming either drug alone “and the sum of the individual treatment effects.” 2 Minute Medicine reports that the combination also improved oral glucose tolerance and insulin sensitivity, reduced fat mass and plasma and liver lipids, and raised lean mass and the lean-to-fat ratio. Body-weight-adjusted energy expenditure did not decline. ERX also reports a 78% reduction in hepatic total cholesterol versus placebo.
ERX’s release says the results “suggest that ERX1000 may help patients taking semaglutide prevent the body from fighting back against weight loss.”
What do mouse results mean for people?
Mouse results often don’t carry over to people. FDA’s roadmap on reducing animal testing says there is “growing scientific recognition that animals do not provide adequate models of human health.” Bracken’s Royal Society of Medicine article says many animal experiments are poorly designed, conducted and analysed, which is one reason they often do not translate into human trials.
Semaglutide’s own label makes the same point. The FDA-approved Wegovy prescribing information says that in rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures, and that it is unknown whether Wegovy causes them in humans.
So the 36% is a mouse number from 35 days, and it says nothing yet about adults. For a plain walk through reading GLP-1 study numbers, see our glp1r variant weight loss study guide.
Is ERX1000 in human trials yet?
ERX1000 is in a Phase 2a human trial assessing safety and tolerability in adults with obesity. The ERX company news page says completion is expected in the second half of 2027. The trial is listed as NCT07570758 on ClinicalTrials.gov, according to a trial-tracking site. ERX says it completed two Phase 1 trials before this one.
Louis Aronne said the findings “support leptin sensitization as a potential strategy” to enhance GLP-1 therapy, and that the combination may let patients lower the GLP-1 dose and reduce side effects. Those are his statements on the company page.
What does leptin resistance mean, according to ERX?
ERX calls ERX1000 a leptin sensitizer. In the company’s framing, the body can fight back against weight loss, and ERX1000 is meant to help with that. The idea that leptin resistance helps explain weight regain on semaglutide is ERX’s hypothesis.
Common mix-ups
- ERX1000 is not semaglutide. It’s a separate oral drug from ERX Pharmaceuticals. Semaglutide is the active drug in Wegovy, which is approved for weight reduction in adults with obesity. If the names blur, our guide to the difference between ozempic and wegovy sorts them out.
- The 36% is not a Wegovy number. Wegovy’s label reports a -14.9% mean weight change against -2.4% on placebo over 68 weeks, in a human trial. The mouse study ran 35 days in animals, so the two studies differ in species and length. Trial percentages depend on the trial, and our wegovy pill weight loss studies page is a useful comparison.
- Two write-ups, one set of numbers. 2 Minute Medicine’s article repeats the company’s figures, so it is not a second study.
- Phase 1 and Phase 2a are not the same. ERX says its two Phase 1 trials are complete. The ongoing Phase 2a trial’s stated focus is safety and tolerability.
Who does this affect?
- If you take semaglutide, or you’re weighing it, this headline is about you. ERX says ERX1000 “may help patients taking semaglutide prevent the body from fighting back against weight loss.” That is ERX’s claim.
- Wegovy’s label covers adults with obesity and people 12 and older with obesity. ERX1000 is not part of that approved use.
- If you take semaglutide now, the people to ask are the doctor who prescribes it and your pharmacist.
Key dates
- Nov. 15, 2026: Louis Aronne presents the data at ObesityWeek 2026, according to 2 Minute Medicine.
- Nov. 16, 2026: ERX issues its news release through PR Newswire.
- Nov. 17, 2026: 2 Minute Medicine publishes its summary.
- 06/2026: revision date on the Wegovy prescribing information.
- Second half of 2027: ERX’s expected completion of the Phase 2a trial.
Questions that settle your next step
- Is ERX1000 approved? No. It is investigational.
- Are there human results for the combination? Not yet.
- When does the human trial finish? ERX expects the second half of 2027.
- Who should you ask about semaglutide? Your prescribing doctor or your pharmacist.
- Where can you follow the trial? A trial-tracking site lists it as NCT07570758; check ClinicalTrials.gov to confirm.
By Sense and Evidence Health Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.